Skip to main content

Table 4 Current PHASE III trials

From: Maintenance therapy in NSCLC: why? To whom? Which agent?

Trial/Author Comparison Comments References
NCT01107626 ECOG 5508 Paclitaxel/Carboplatin/Bevacizumab, followed by pemetrexed vs bevacizumab vs pemetrexed/bevacizumab not yet open for recruitment [39]
NCT00789373 Paz-Ares LG Maintenance Pemetrexed/BSC Vs BSC Immediately Following Induction Treatment With Pemetrexed + Cisplatin for Advanced Nonsquamous NSCLC currently recruiting [39]
NCT00762034 Patel et al. Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab vs Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in IIIB or IV Nonsquamous NSCLC currently recruiting [39]
NCT00820755 NEXT Platinum-based chemotherapy plus cetuximab followed by cetuximab as maintenance with either 500 mg/m2 every 2 w or 250 mg/m2 every w ongoing, not recruiting [39]
NCT00948675 Zinner et al. Pemetrexed/carboplatin with maintenance pemetrexed vs paclitaxel/carboplatin/bevacizumab with maintenance bevacizumab in IIIB or IV Nonsquamous NSCLC currently recruiting [39]
NCT00693992 CALGB 30607 Sunitinib as maintenance therapy vs placebo in Non-Progressing Patients Following 4 Cycles of Platinum-Based Combination in IIIB/IV NSCLC currently recruiting [39]
NCT00961415 AVAPERL1 Bevacizumab with or without pemetrexed as maintenance after 4 cycles Bevacizumab/Cisplatin/Pemetrexed currently recruiting [39]
NCT00676507 STOP Lucanix™ (Belagenpumatucel-L) as Maintenance III/IV NSCLC with SD or PR and Who Have Responded to or Have Stable Disease Following One Regimen of Front-line, Platinum-based Combination Chemotherapy currently recruiting [39]